Trials / Completed
CompletedNCT03159403
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 325 (actual)
- Sponsor
- Melinta Therapeutics, Inc. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study is a retrospective, observational study to evaluate oritavancin use in participants under real world conditions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Oritavancin | This study is an observational study. All participants were administered oritavancin prior to enrollment in this study. |
Timeline
- Start date
- 2017-04-12
- Primary completion
- 2018-02-15
- Completion
- 2018-03-08
- First posted
- 2017-05-18
- Last updated
- 2018-03-12
Locations
21 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03159403. Inclusion in this directory is not an endorsement.